Status: Recruiting
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
Participants needed: 1,112
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Biocells (Beijing) Biotech Co.,LtdUpdated: Apr 9, 2026Locations: 9
Eligibility criteria
Age18~85 (including 18 and 85 years)，no gender limitation; [+5]
Imaging confirmed intracranial hemorrhagic disease (hemorrhagic stroke, epidural... [+17]